The Gilenya Pregnancy Registry
Recruiting
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.
Gender:
Female
Ages:
All
Trial Updated:
03/10/2023
Locations: Novartis Investigative Site, Grand Forks, North Dakota
Conditions: Multiple Sclerosis